Tramiprosate API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Tramiprosate is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Tramiprosate or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Tramiprosate API 3687-18-1?

Description:
Here you will find a list of producers, manufacturers and distributors of Tramiprosate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Tramiprosate 
Synonyms:
 
Cas Number:
3687-18-1 
DrugBank number:
DB06527 
Unique Ingredient Identifier:
5K8EAX0G53

General Description:

Tramiprosate is a chemical compound identified by the CAS number 3687-18-1. It is known for its distinct pharmacological properties and applications.

Indications:

This drug is primarily indicated for: Investigated for use/treatment in strokes and alzheimer's disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Classification:

Tramiprosate belongs to the class of organic compounds known as organosulfonic acids. These are compounds containing the sulfonic acid group, which has the general structure RS(=O)2OH (R is not a hydrogen atom), classified under the direct parent group Organosulfonic acids. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Organic sulfonic acids and derivatives class, specifically within the Organosulfonic acids and derivatives subclass.

Categories:

Tramiprosate is categorized under the following therapeutic classes: Alkanes, Alkanesulfonic Acids, Anticonvulsants, Carbohydrates, Central Nervous System Agents, Central Nervous System Depressants, GABA Agents, GABA Agonists, Hydrocarbons, Acyclic, Neurotransmitter Agents, Sulfonic Acids, Sulfur Acids, Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Tramiprosate is a type of Anticonvulsants


Anticonvulsants are a vital category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used for the treatment of seizures and epilepsy. These APIs play a crucial role in managing and preventing convulsions, which are characterized by abnormal electrical activity in the brain. With a significant demand for effective anticonvulsant medications, these APIs hold immense importance in the pharmaceutical industry.

Anticonvulsant APIs work by stabilizing the excessive electrical activity in the brain, preventing or reducing seizures. They achieve this by targeting specific receptors or channels involved in the regulation of neuronal excitability. Some commonly used anticonvulsant APIs include phenytoin, valproic acid, carbamazepine, and lamotrigine.

Pharmaceutical companies utilize these APIs to formulate various dosage forms, such as tablets, capsules, and oral suspensions, ensuring convenient administration for patients. Additionally, anticonvulsant APIs may also be employed in the development of extended-release formulations, providing sustained and controlled drug release.

The market for anticonvulsant APIs continues to grow due to the rising prevalence of epilepsy and other seizure disorders. Moreover, ongoing research and development efforts aim to enhance the efficacy, safety, and tolerability of these APIs, ensuring better treatment outcomes for patients.

In conclusion, anticonvulsant APIs are a crucial pharmaceutical category used to manage seizures and epilepsy. With their ability to stabilize brain activity, these APIs play a pivotal role in improving the quality of life for individuals living with these conditions. The pharmaceutical industry's continued focus on research and development in this area ensures the availability of advanced and effective anticonvulsant medications for patients in need.